+231.8%
GM vs GSK
+170.8%
+61.1%
-60.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.5% | -2.3% | +2.8% | +1.5% |
| 7D | -5.2% | -3.0% | -2.2% | -4.0% |
| 30D | +0.1% | +0.4% | -0.2% | -0.2% |
| 3M | -0.2% | -1.2% | +1.0% | -0.1% |
| 6M | +12.8% | +0.9% | +11.8% | +11.4% |
| YTD | +4.0% | +4.0% | 0.0% | +0.9% |
| 1Y | +24.8% | +7.3% | +17.5% | +19.3% |
| 3Y | +209.0% | +57.1% | +151.9% | +134.4% |
| 5Y | +35.7% | +43.0% | -7.2% | +5.9% |
| 10Y | +203.2% | +103.1% | +100.2% | +88.5% |
| All | +231.8% | +170.8% | +61.1% | +59.6% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling